What Are the Limitations of Current Studies on Cannabis and Trigeminal Neuralgia?

PostedFebruary 22, 2026

UpdatedFebruary 22, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

While interest in cannabis for trigeminal neuralgia is growing, understanding cannabis research limitations is crucial. Current studies offer some promising insights but often fall short of delivering robust, universally applicable results. Researchers face several challenges that make it difficult to draw firm conclusions.

Key Cannabis Research Limitations

These limitations highlight why more comprehensive research is needed to guide both patients and healthcare providers.

Small Sample Sizes

Many studies involve small sample sizes, which reduces the reliability of findings and makes it difficult to generalise results.

Study Design

Weak or inconsistent study design often limits the strength of conclusions, as not all research follows rigorous methods.

Evidence Gaps

There are significant evidence gaps in long-term safety, dosing strategies, and the effectiveness of cannabis for trigeminal neuralgia.

Lack of Standardisation

Variability in cannabis products and delivery methods makes it hard to compare results across different trials.

Limited Patient Diversity

Most studies include narrow patient groups, which may not reflect the experiences of all individuals affected by trigeminal neuralgia.

Addressing these cannabis research limitations is essential for advancing knowledge and creating better treatment strategies. By overcoming issues like small sample sizes, poor study design, and ongoing evidence gaps, future research can provide stronger and more reliable answers for patients seeking relief.

If you’re exploring cannabis treatment options for trigeminal neuralgia, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and trigeminal neuralgia.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.